0.53
0.53 (0%)
As of Apr 17, 2025
Veru Inc. [VERU]
Source:
Company Overview
Veru Inc is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin.
| Country | United States |
| Headquarters | miami, florida |
| Phone Number | 3125959123 |
| Industry | manufacturing |
| CEO | Mitchell S. Steiner |
| Website | verupharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-10.2 |
| Net Income | $-8.9 |
| Net Cash | $1.7 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -17.9% |
| Profit as % of Stockholder Equity | -33.6% |
Management Effectiveness
| Return on Equity | -33.6% |
| Return on Assets | -22.5% |
| Turnover Ratio | |
| EBITA | $-10.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $39.8 |
| Total Liabilities | $13.2 |
| Operating Cash Flow | $-11.3 |
| Investing Cash Flow | $17.2 |
| Financing Cash Flow | $-4.2 |
